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Objectives: The self-expanding nitinol stent, LifeStent (Bard Periph-
eral Vascular, Tempe, Ariz), is commonly used in endovascular interven-
tions for superﬁcial femoral and popliteal arterial stenosis. Food and
Drug Administration approval of the device was based on the RESIL-
IENT trial, which demonstrated LifeStent utilization having superior
angiographic results and patency rates at 12 months compared with angio-
plasty alone. Patient inclusion criteria in the RESILIENT trial were highly
stringent and excluded patients with critical limb ischemia. The purpose of
our study was to determine outcomes of patients receiving the LifeStent
for peripheral arterial disease including individuals with severe disease
progression.
Methods: All patients receiving a LifeStent during femoropopliteal
endovascular interventions between June 2006 and May 2012 with
duplex-ultrasound/angiographic follow-up or limb amputation were
reviewed. Patients with acute limb ischemia or previous revascularization
in the limb of interest were excluded. Patient demographics, Rutherford
classiﬁcation and anatomic factors (TransAtlantic Inter-Society Consensus
[TASC] II classiﬁcation, lesion length, and runoff vessel status) were deter-
mined. Outcomes evaluated included limb patency and freedom from limb
loss. Loss of primary patency deﬁned as vessel occlusion or needed for target
vessel revascularization.
Results: A total of 321 procedures in 272 patients employed the
LifeStent during the study time period, with 252 procedures having
duplex-ultrasound/angiographic follow-up. Eight-six procedures were
excluded from analysis due to limbs having acute limb ischemia or
a prior stent or bypass graft, leaving for analysis 166 limbs in 151
patients having the LifeStent utilized in de novo vessels (54% male;
mean age, 68 6 12 years). Eighty percent did not meet RESILIENT
criteria. Exclusion included a Rutherford category greater than 3
(51%), TASC II classiﬁcations C/D (51%), zero runoff vessels to the
foot (6%) or stent placement outside the zone deﬁned (18%). Median
follow-up period for patency was 8 months (range, 6 days to 37
months). Primary patency rates for all limbs were 81% at 6 months
and 50% at 12 months. TASC II classiﬁcation did not signiﬁcantly
affect rates of primary patency (P ¼ .30) or primary-assisted patency
(P ¼ .43). Predictors for loss of primary patency included vessel occlu-
sion (P ¼ .01) and the absence of clopidogrel at discharge (P ¼ .001).
Fifteen limbs were amputated with freedom from limb loss at 12
months being 92%. A preintervention Rutherford category greater
than 3 predicted limb lost (P ¼ .01).
Conclusions: The LifeStent is a viable option for patients with periph-
eral arterial disease regardless of disease severity.
Most Complications of Common Femoral Endarterectomy Occur after
Hospital Discharge
Bao-Ngoc H. Nguyen, Richard Neville, Mustafa Abugideiri, Rodeen
Rahbar, Richard Aur, Anton Sidawy. George Washington University, D.C.
Objectives: Common femoral endarterectomy for limited arterial
occlusive disease is performed commonly because it is considered a short
and fairly low-risk procedure. This study investigates the timing of 30-day
outcomes of this procedure.
Methods: All patients who underwent common femoral endarterec-
tomy in the National Surgical Quality Improvement Program database
between 2005 and 2010 were selected. After the procedure’s mortality
and morbidities were identiﬁed, we speciﬁcally focused on the timing of
event occurrences before and after hospital discharge.
Results: There were a total of 1843 common femoral endarterecto-
mies performed during that period. The average operative time was 146 6
69.5 minutes, and 10% of patients needed to return to the operating
room. The average length of stay was 4 6 5.8 days; 90% of patients
were discharged within 1 week of surgery. Although cardiovascular events,
renal dysfunction, and pulmonary complication rates were relatively low
(Table), there was a 3.4% mortality rate, almost one-half of which
occurred after the ﬁrst week. Wound infection rate was 3%; 94% of which
occurred after the ﬁrst week. Overall, there was a 10% rate of combined
mortality/morbidity, and more than 60% of these events occurred after
the ﬁrst week.
Conclusions: Although common femoral endarterectomy is consid-
ered a relatively benign procedure, it still has signiﬁcant complication rate.
However, a signiﬁcant percentage of these complications occurred after
patients are discharged from the hospital. Close postoperative follow-up
should be considered.Table. Thirty-day outcomes and timing of event occurrence after
common femoral endarterectomy
Weeks after surgeryn ¼ 1843
Events
n (%) 1 2 3 $4Mortality 62 (3.4%) 31 (53.5%) 12 (20.7%) 4 (6.9%) 11 (19.0%)
Graft failure 21 (1.1%) 8 (38.1%) 7 (33.3%) 3 (14.3%) 3 (14.3%)
Cardio 27 (1.5%) 19 (70.4%) 4 (14.8%) 1 (3.7%) 3 (11.1%)
Clot 25 (1.4%) 8 (32.0%) 6 (24.0%) 8 (32.0%) 3 (12.0%)
Renal 16 (0.9%) 10 (62.5%) 4 (25.0%) 2 (12.5%) 0 (0%)
Pneumo 61 (3.3%) 38 (63.3%) 11 (18.3%) 8 (13.3%) 3 (5.0%)
Wound 49 (2.7%) 3 (6.1%) 20 (40.8%) 14 (28.6%) 12 (24.5%)
Sepsis 47 (2.6%) 12 (26.7%) 19 (42.2%) 7 (15.6%) 7 (15.6%)
Composite 191 (10.4%) 68 (36.2%) 51 (27.1%) 37 (19.7%) 32 (17.0%)Rapid Fire Presentations
Branched Surgical Grafts for Aortic Reconstruction in Connective
Tissue Disorder Patients: The Emerging Standard for Repair
Dean J. Arnaoutakis, Brandon W. Propper, Natalia O. Glebova, Ying Wei
Lum, Christopher J. Abularrage, James H. Black III. The Johns Hopkins
Hospital, Baltimore, Md
Objectives: Connective tissue disorders (CTD) can predispose
patients to aneurysmal dilation of the entire aorta. Carrel patch or inclusion
patches have been a long standing method for branch reconstruction but
leaves aortic tissue at risk for recurrent aneurysm after repair. Furthermore,
re-do aortic procedures carry substantially higher procedural risk than index
operations and, thus, should be avoided. The purpose of this study is to
evaluate the performance of branched surgical grafts for aortic reconstruc-
tion in thoracoabdominal aortic aneurysms in CTD patients.
Methods: Patient records from the Johns Hopkins Hospital between
August of 2006 and January 2013 were evaluated. Twenty patients were identi-
ﬁed with CTD and underwent branched renovisceral reconstruction for either
typeI, II, orIII thoracoabdominal aortic aneurysms.Follow-updata and imaging
were retrospectively reviewed for technical and postoperative complications.
Results: A total of 20 patients, with an average age of 45 (17-67) years,
were reconstructed with branched Gelweave grafts on left atriofemoral
bypass. Overall mortality was 10% with both deaths occurring in the early
postoperative period (aortic arch rupture at 96 hours and cerebral hemor-
rhage at 120 hours). Of the 18 surviving patients (10 women, 8 men), 64
visceral vessels were reconstructed with a mean follow-up of 23.6 months
(range, 3-47 months). Two renal artery bypasses thrombosed (clinically
silent) in follow-up, yielding a branch patency rate of 97%. Median preoper-
ative creatinine was 0.81 (0.4-1.3) mg/dL and median postoperative creati-
nine was 1.1 (0.4-3.3) mg/dL (P ¼ 0.4). There were no mesenteric
complications or need for hemodialysis. No patients required exploration
for bleeding or secondary procedures to assist in visceral patency, and none
suffered spinal cord injury. On follow-up, there was no additional aneurysmal
degeneration in the replaced aortic segment or renovisceral branches.
Conclusions: Branched aortic surgical grafts eliminate the aorta at risk
for recurrent aneurysms. Branched reconstruction is durable and should be
the method of choice for repair of complex thoracoabdominal aneurysms
in patients with CTD. Furthermore, this technique may benchmark compar-
ison with emerging branched endovascular technology in patients with CTD.
Preoperative Smoking Cessation is Essential in Preventing Early Graft
Failure after Infrainguinal Bypass Surgery
Shalini Selvarajah, Mahmoud B. Malas, James H. Black III, Ying W. Lum,
Brandon W. Propper, Christopher J. Abularrage. Johns Hopkins Hospital,
Baltimore, Md
Objectives: Smoking has been implicated as the single most important
risk factor for the development of peripheral arterial disease (PAD). While
previous studies have found poor long-termoutcomes in smokers undergoing
lower extremity bypass, little data exists as to the effects of persistent tobacco
abuse on the early outcomes of infrainguinal bypass on a national level.
Methods: The American College of Surgeons-National Surgical
Quality Improvement Program database from 2005-2011 was queried for
all patients undergoing infrainguinal bypass. A bivariate analysis was done
to assess pre- and intraoperative risk factors for the primary outcome of
30-day graft failure stratiﬁed by current smoking status. The American
College of Surgeons-National Surgical Quality Improvement Program
considers patients to be nonsmokers if they did not smoke for 12 months
